NanoMab joins U.K. radionuclide therapy project

By staff writers

June 10, 2020 -- Biopharmaceutical firm NanoMab has signed on as an industrial partner in the U.K. Engineering and Physical Research Council (EPSRC) Programme for Next-Generation Imaging and Therapy with Radionuclides (MITHRAS).

Launched on 8 June, MITHRAS is a collaborative partnership between King's College London, Imperial College, and Southampton University, as well as nuclear medicine companies. The program has been awarded 6 million pounds (6.73 million euros) by the EPSRC and is being led by Prof. Phil Blower, chair in imaging chemistry in the Division of Imaging Sciences and Biomedical Engineering at King's College London.

NanoMab said it's working with King's College London to initiate a clinical study for a SPECT-based imaging agent that enables acquisition of images of PD-L1 distribution on different tumors in the body before, during, and after treatment.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking